




Curriculum Vitae

Personal Information		
Title	Dr.	
Name	Takayuki Yamamoto	
Degree	M.D., PhD., F.A.C.G.	
Country	Japan	
Affiliation	Yokkaichi Hazu Medical Center	
Educational Background		
1989: M.D., Mie University School of Medicine 1996: Ph.D. Mie University		
Professional Experience		
1989-1991: Resident, Second Department of Surgery, Mie University School of Medicine 1991-2001: Medical Staff, Second Department of Surgery, Mie University School of Medicine 1997-1998: Research Fellow, Department of Surgery, The University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK (Professor Michael R.B. Keighley) 2001-Present: Chief, Department of Surgery & Inflammatory Bowel Disease Center, Yokkaichi Social Insurance Hospital 2005-2006: Research Fellow, Department of Colorectal Surgery, The Cleveland Clinic Foundation, Ohio, US (Dr. Victor W. Fazio) 2009-Present: Clinical Professor, Mie University School of Medicine 2022-Present: Vice President, Yokkaichi Hazu Medical Center		
Professional Organizations		
International Organization for the Study of Inflammatory Bowel Disease (IOIBD) The International Society of Surgery (ISS)/Société Internatioinale de Chirurgie (SIC) The European Crohn's and Colitis Organisation (ECCO) American College of Gastroenterology (ACG) The American Society of Colon and Rectal Surgeons (ASCRS) Japan Surgical Society Japanese Society of Gastroenterological Surgery The Japanese Society of Gastroenterology The Japan Society of Coloproctology		
Main Scientific Publications		
Yamamoto T, et al. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: A prospective pilot study. <i>Inflamm Bowel Dis</i> 2009; 15: 1460-6. Yamamoto T, et al. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. <i>J Crohns Colitis</i> 2012; 6: 750-5. Yamamoto T, et al. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. <i>Aliment Pharmacol Ther</i> 2015; 42: 549-58. Yamamoto T, et al. Consecutive monitoring of fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. <i>Am J Gastroenterol</i> 2015; 110: 881-7. Yamamoto T, et al. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. <i>Aliment Pharmacol Ther</i> 2016; 43: 705-16.		